Notable
Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma
Recruitment resumed after suspension
Also in this update: Primary completion pushed from Dec 31, 2026 to Mar 2027; Enrollment reduced: 30 → 25 participants
Melissa LumishPhase 2 NCT06044311 Registry history of NCT06044311 on ClinicalTrials.gov (opens the registry)
Updated